Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease
Casey Mcdonald Daniel Kontoh Boateng Lisa Ricciardi Steven Weissman International Journal Of Molecular Science Alzheimer Association International Conference
Source: eagletribune.com